Key terms
About DCPH
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. The company was founded by Peter A. Petillo and Daniel L. Flynn in 2003 and is headquartered in Waltham, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest DCPH news
May 02
11:10am ET
Biotech Alert: Searches spiking for these stocks today
May 01
10:51am ET
Biotech Alert: Searches spiking for these stocks today
Apr 30
9:45am ET
Boeing, Paramount downgraded: Wall Street’s top analyst calls
Apr 30
6:53am ET
Biotech Sector: M&A Fuels Renewed Excitement
Apr 29
5:27pm ET
Deciphera upgraded to Equal Weight from Underweight at Barclays
Apr 29
4:31pm ET
Deciphera downgraded to Market Perform from Outperform at JMP Securities
Apr 29
3:48pm ET
Deciphera downgraded to Market Perform from Outperform at Leerink
Apr 29
3:15pm ET
Deciphera Pharmaceuticals (DCPH) was downgraded to a Hold Rating at JMP Securities
Apr 29
1:49pm ET
Deciphera downgraded to Neutral from Buy at Guggenheim
Apr 29
10:29am ET
Deciphera downgraded to Hold from Buy at JonesResearch
Apr 29
10:11am ET
Deciphera downgraded to Hold from Buy at Jefferies
Apr 29
8:49am ET
Deciphera downgraded to Neutral from Overweight at Piper Sandler
Apr 29
7:11am ET
Deciphera to resume trading at 7:30 am ET
Apr 29
7:09am ET
Deciphera to be acquired by ONO Pharmaceutical for $25.60 per share in cash
Apr 22
8:32am ET
Piper Sandler Sticks to Their Buy Rating for Deciphera Pharmaceuticals (DCPH)
Apr 08
8:40am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Deciphera Pharmaceuticals (DCPH) and Shockwave Medical (SWAV)
Feb 21
6:51am ET
Barclays Keeps Their Sell Rating on Deciphera Pharmaceuticals (DCPH)
Feb 07
8:40am ET
Stifel Nicolaus Remains a Buy on Deciphera Pharmaceuticals (DCPH)
Feb 07
8:31am ET
Buy Rating Reaffirmed for Deciphera Pharmaceuticals on Strong Q4 Performance and Promising Drug Prospects
Feb 07
6:20am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Feb 07
5:19am ET
Deciphera Pharmaceuticals (DCPH) Gets a Sell from Barclays
Feb 07
12:50am ET
Analysts Are Bullish on Top Healthcare Stocks: Deciphera Pharmaceuticals (DCPH), ACADIA Pharmaceuticals (ACAD)
Feb 06
12:45pm ET
Deciphera Pharmaceuticals: Strong Buy Rating on Robust Financials and Promising Pipeline
Feb 06
11:35am ET
Deciphera Pharmaceuticals: Sustained Growth and Market Expansion Drive Buy Rating
Feb 06
7:08am ET
Deciphera sees NDA submission for Vimseltinib in 2Q24
Feb 06
7:08am ET
Deciphera sees NDA submission for Vimseltinib in 2Q24
Feb 06
7:04am ET
Deciphera reports Q4 EPS (54c), consensus (58c)
DCPH Financials
Key terms
Ad Feedback
DCPH Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
DCPH Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
